64th American Society of Hematology Annual Meeting and Exposition (ASH 2022)

New Orleans, Louisiana, US 10 December 2022 - 13 December 2022

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

08 Feb 2023 by

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

08 Feb 2023

Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?

06 Feb 2023 by

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?

06 Feb 2023

Durable benefits with beti-cel therapy in beta-thalassaemia

26 Jan 2023 by

One-time ex-vivo gene therapy with betibeglogene autotemcel (beti-cel) reduces the need for transfusion in patients with transfusion-dependent beta-thalassaemia in an analysis of studies presented at ASH 2022.

Durable benefits with beti-cel therapy in beta-thalassaemia

26 Jan 2023

Efgartigimod tied to sustained platelet count increase in patients with ITP

24 Jan 2023 by

Treatment with efgartigimod, a neonatal Fc receptor (FcRn) antagonist, in patients with chronic or persistent immune thrombocytopenia (ITP) resulted in a higher proportion of patients achieving a sustained platelet count response compared with placebo, according to the ADVANCE IV* trial presented at ASH 2022.

Efgartigimod tied to sustained platelet count increase in patients with ITP

24 Jan 2023

Device filters out direct thrombin inhibitor from plasma for routine haemostasis tests

23 Jan 2023 by

A user-friendly medical device can effectively remove the direct thrombin inhibitor (DTI) argatroban from plasma in a rapid and ergonomic manner, as shown in the results of a study presented at ASH 2022.

Device filters out direct thrombin inhibitor from plasma for routine haemostasis tests

23 Jan 2023

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023 by

Use of FRSW 107, a novel homodimer recombinant factor VIII (rFVIII) Fc fusion protein, for prophylaxis and treatment of bleeding episodes is both safe and effective among previously treated adolescent and adult patients with haemophilia A (HA), reports a China study presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023 by

Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023

Mitapivat maintains long-term Hb response in PK deficiency patients

19 Jan 2023 by

Treatment with mitapivat results in long-term and durable improvements in haemoglobin (Hb) and a decrease in transfusion burden over several years in patients with pyruvate kinase (PK) deficiency, according to the results of a study, which was presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Mitapivat maintains long-term Hb response in PK deficiency patients

19 Jan 2023

It’s time to do away with neutropenic diet post-HSCT – experts

17 Jan 2023 by

Adopting a low-microbial, protective (neutropenic) diet offers no clear benefit to patients following hematopoietic stem cell transplantation (HSCT) in a study described as the first to investigate the role of neutropenic diet post-HSCT.

It’s time to do away with neutropenic diet post-HSCT – experts

17 Jan 2023

$PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib$

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib

15 Jan 2023 by

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib

15 Jan 2023